Akari Therapeutics announces strategic partnership with WuXi XDC to advance development of its novel ADC payload targeting RNA splicing

CAR-T Digest - August 2020

Weekly Digest - April 2026

06 April 2026: Akari Therapeutics announces strategic partnership with WuXi XDC to advance development of its novel ADC payload targeting RNA splicing

Akari Therapeutics has entered into a strategic partnership with WuXi XDC to advance its novel RNA splicing targeting ADC payload, marking a key step in accelerating development of its next-generation oncology platform
The partnership is anchored by Akari’s proprietary PH1 payload, a first‑in‑class spliceosome modulator designed to interfere with RNA splicing in cancer cells, enabling a distinct and innovative mechanism of action relative to established ADC payload technologies
The collaboration is expected to support IND-enabling activities and position Akari to file an IND for its lead program, AKTX-101, by late 2026, reflecting a faster path toward clinical evaluation
AKTX-101, the lead program incorporating PH1, is initially being developed for metastatic urothelial cancer, where treatment options remain limited, particularly in the second-line setting
With encouraging preclinical anti-tumor activity and the potential to combine direct cytotoxic effects with immune activation, the PH1 platform positions Akari to contribute to the next wave of innovation in ADC payload development